Cheers to our global gang! 🌍🌟 As the year draws to a close, we're giving a shoutout to the 13,000 amazing contributors on our platform. By leveraging Byron, the exchange within our company becomes more seamless, paving the way for new projects and strengthening our unity within Bayer. 🚀 Presenting this exclusive POAP as a massive thank you, because without you, this platform wouldn't be what it is. 🙌 Byron, an acronym for Bayer Open Network, is our Skills database for Bayer employees, including speed networking. We kicked off in 2018 as a True North grassroots side initiative, going live in 2020. Created by over 40 students and programming enthusiasts with the help of EY Croatia. Today, we have 13,000 registered users from 89 countries, in 293 cities. People have searched for something in Byron at least 25,000 times and engaged in 31,000 1:1 Speed network meetings. http://go/byron Looking ahead, we're thrilled about the future and the prospect of our community growing even larger. Can't wait for more collaborations and successes together in the coming year! 🎉✨ Art created by Lena Schermer

The Bayer Pharma Data Science & Artificial Intelligence (DS&AI) F2F meeting in Madrid was a great event! The motto Connect, Clarify & Commit came to life as we connected during networking sessions, breakout sessions and social events. At the poster session we learned about our progress embedding a product mindset and driving operational excellence, closely collaborating with our partners across R&D. We heard presentations, took part in discussions, unconference sessions, asked questions and shared ideas, setting foundations for the growth of DS&AI beyond 2023. The use of POAPs was a definite social success and I am sure you did not miss Jesús’ enthusiasm as he gave an overview of this new tool. By promoting its use, we drive new ways of using this sustainable and effective tool, ultimately helping to innovate its use by doctors, within clinical trials, for patients and more. There were fun elements as well, like the final night, where our very own flash-mob took to the dance floor and we danced until way past midnight! All this was made possible by the org team: Anke Ebert, Larsen Schnadhorst, Kathleen Thies, Sheila Elz, Stefanie Holt-Noreiks and Claudia Vogt. They have done an excellent job coordinating the event, with the perfect balance of presentations, speakers, entertainment, and networking. Now let us make sure we continue to further the impact we have on bringing innovative medicines to our patients. Sai Jasti, Head of DS&AI https://bayer.com/poap

With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

Thanks for for taking the time to complete this survey, It was a pleasure seeing you in Madrid!

I studied piano performance and toxicology, and am now Master Data Manager at Bayer Pharma in the R&D Master Data Management team of Data Science & AI. I am passionate about team collaboration and rowing. Currently, I'm co-leading the IDMP Ontology, an international cross-industry project with 12 pharma companies for the unique identification of medicinal products to ensure patient safety. Talk to me about common standards and high quality data for better ML and AI outcomes, our next collaboration project, and/or our next jam session at the Bayer Berlin campus.

Nice to meet you!

I am passionate about harnessing data and cutting-edge technologies to optimize the clinical impact of cancer drugs and diagnostics. Drawing from my personal experiences with cancer, I am devoted to developing analytical systems that integrate clinical, imaging, and biomarker data to provide real-time access to high-quality information. Throughout my career, I have worked closely with clinical teams, advocating for data-driven decision-making and uncovering insights into clinical realities. I strongly believe that by leveraging complex datasets, we can gain a deeper understanding of cancer biology, and subsequently improve our decision-making processes. This adaptable approach empowers us to address fundamental questions, such as which targets to pursue, which technologies to invest in, which drugs to prioritize, and ultimately, which therapies are best suited for individual patients.

I am a curious leader of smart and cool people and together we drive the digital transformation of our Pharma Research and Early development functions.